Drug Trial Radar · NCT02733614
Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
33
Actual
Start
Dec 2016
Primary completion
Oct 2020
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Weill Medical College of Cornell University; United States Department of Defense; U.S. Army Medical Research and Development Command
- First posted
- Apr 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a double-blind fashion to 2 groups in a crossover design. The first group will receive SRX246 for 8 weeks followed by 8 weeks of placebo, while the second group will receive placebo for 8 weeks followed by 8 weeks of SRX246. Both groups will engage in a 7-day washout period between treatments. Subjects will be assessed at baseline and then every 2 weeks during the trial using the CAPS.
Conditions
- PTSD
Interventions
SRX246Drug
novel V1a receptor antagonist
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of overall clinical improvementTime frame: 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Weill Cornell Medical College
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.